Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- University Hospital, Antwerp
- Target Recruit Count
- 10
- Registration Number
- NCT00834002
- Locations
- 🇧🇪
Antwerp University Hospital/Center for Cellular Therapy and Regenerative Medicine, Edegem, Belgium
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2020-12-22
- Target Recruit Count
- 51
- Registration Number
- NCT00831766
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Intensive Salvage Therapy
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT00822094
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation
- Conditions
- Chronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome-Refractory Anemia With Excess Blasts
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 33
- Registration Number
- NCT00809250
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)
- Conditions
- AML
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Thomas A. Lane, MD
- Target Recruit Count
- 6
- Registration Number
- NCT00808080
- Locations
- 🇺🇸
UCSD, La Jolla, California, United States
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Drug: 5-Azacitidine
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 30
- Registration Number
- NCT00795548
- Locations
- 🇩🇪
Universitaetsklinik Heidelberg, Medizinische Klinik und Poliklinik V, Heidelberg, Baden-Wuertemberg, Germany
🇩🇪Klinikum der Johann-Wolfgang-Goethe Universität, Medizinische Klinik II, Frankfurt, Hessen, Germany
🇩🇪Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, NW, Germany
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 122
- Registration Number
- NCT00778375
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: 5-Azacitidine
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 50
- Registration Number
- NCT00766116
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Northside Hospital/BMTGA, Atlanta, Georgia, United States
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
- Conditions
- AML
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 130
- Registration Number
- NCT00744081
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Leukaemia, Myelocytic, Acute
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT00725283
- Locations
- 🇫🇷
GSK Investigational Site, Grenoble cedex 9, France